|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:boosterDoseAge
|
16 years
|
|
gptkbp:brand
|
gptkb:Menveo
gptkb:Nimenrix
gptkb:Menactra
|
|
gptkbp:broadcastOn
|
2 doses for adolescents
|
|
gptkbp:contains
|
polysaccharide antigens
conjugate protein
|
|
gptkbp:developedBy
|
prevention of meningitis outbreaks
|
|
gptkbp:firstDoseAge
|
11-12 years
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
MenACWY vaccine
|
|
gptkbp:prevention
|
meningococcal disease
|
|
gptkbp:protectedBy
|
gptkb:Neisseria_meningitidis_serogroup_A
gptkb:Neisseria_meningitidis_serogroup_C
gptkb:Neisseria_meningitidis_serogroup_Y
Neisseria meningitidis serogroup W
|
|
gptkbp:recommendation
|
adolescents
people with certain medical conditions
travelers to high-risk areas
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
pain at injection site
|
|
gptkbp:usedIn
|
gptkb:Europe
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:WHOStatus
|
gptkb:World_Health_Organization_Model_List_of_Essential_Medicines
|
|
gptkbp:bfsParent
|
gptkb:Neisseria_meningitidis_serogroup_W-135
|
|
gptkbp:bfsLayer
|
7
|